Henry Schein, Inc. $HSIC Holdings Lowered by Universal Beteiligungs und Servicegesellschaft mbH

Universal Beteiligungs und Servicegesellschaft mbH cut its stake in Henry Schein, Inc. (NASDAQ:HSIC) by 24.7% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 47,224 shares of the company’s stock after selling 15,477 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH’s holdings in Henry Schein were worth $3,134,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. Ameriprise Financial Inc. boosted its stake in Henry Schein by 3,275.2% during the 2nd quarter. Ameriprise Financial Inc. now owns 2,266,858 shares of the company’s stock valued at $165,594,000 after purchasing an additional 2,199,695 shares in the last quarter. Norges Bank bought a new stake in shares of Henry Schein in the 2nd quarter worth $89,476,000. M.D. Sass LLC acquired a new stake in shares of Henry Schein in the second quarter valued at $79,201,000. Schroder Investment Management Group boosted its stake in Henry Schein by 149.3% during the second quarter. Schroder Investment Management Group now owns 1,563,899 shares of the company’s stock valued at $114,243,000 after buying an additional 936,471 shares in the last quarter. Finally, Bank of America Corp DE boosted its stake in Henry Schein by 204.2% during the second quarter. Bank of America Corp DE now owns 995,375 shares of the company’s stock valued at $72,712,000 after buying an additional 668,182 shares in the last quarter. Institutional investors and hedge funds own 96.62% of the company’s stock.

Henry Schein Trading Down 2.3%

NASDAQ HSIC opened at $75.08 on Thursday. The firm’s 50 day moving average price is $76.18 and its two-hundred day moving average price is $70.73. The company has a debt-to-equity ratio of 0.54, a quick ratio of 0.79 and a current ratio of 1.40. Henry Schein, Inc. has a twelve month low of $60.56 and a twelve month high of $82.49. The stock has a market cap of $8.84 billion, a price-to-earnings ratio of 23.76, a PEG ratio of 2.29 and a beta of 0.88.

Henry Schein (NASDAQ:HSIC) last issued its earnings results on Tuesday, November 4th. The company reported $1.38 EPS for the quarter, topping the consensus estimate of $1.27 by $0.11. Henry Schein had a return on equity of 14.76% and a net margin of 3.02%.The business had revenue of $3.34 billion during the quarter, compared to analysts’ expectations of $3.28 billion. Henry Schein has set its FY 2025 guidance at 4.880-4.960 EPS. Equities analysts anticipate that Henry Schein, Inc. will post 4.74 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on HSIC shares. JPMorgan Chase & Co. upped their price target on shares of Henry Schein from $76.00 to $78.00 and gave the company an “overweight” rating in a report on Wednesday, November 5th. Barrington Research set a $79.00 target price on shares of Henry Schein and gave the stock an “outperform” rating in a report on Wednesday, November 5th. Weiss Ratings reissued a “hold (c)” rating on shares of Henry Schein in a research note on Monday, December 29th. Morgan Stanley raised their target price on shares of Henry Schein from $55.00 to $58.00 and gave the stock an “underweight” rating in a report on Wednesday, November 5th. Finally, Barclays assumed coverage on shares of Henry Schein in a research report on Monday, December 8th. They issued an “overweight” rating and a $86.00 price target on the stock. Five investment analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $76.42.

About Henry Schein

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.